Table 2 Comparison between group 1 (pts received viral vector-based vaccines with adverse events) vs group 2 (pts received mRNA-based vaccines with adverse events)
Viral vector vaccine | Percentage | mRNA vaccines | Percentage | DIFF/95 CI/chi-squared/DF/significance | |
|---|---|---|---|---|---|
Thrombosis/thrombocytopenia | 236 | 51.30% | 1 | 0.20% | 51.1%/46.4340–55.6410%/313.779/1/p < 0.0001 |
ICH | 33 | 7% | 0 | 0 | 7%/4.8418–9.7052%/33.332/1/p < 0.0001 |
DIC | 5 | 1% | 0 | 0 | 1%/− 0.0148–2.3981%/4.618/1/P = 0.0316 |
GBS | 16 | 4% | 5 | 1% | 3%/0.9911–5.2812%/8.483/1/P = 0.0036 |
Acute TM | 7 | 2% | 1 | 0.20% | 1.8%/0.4357–3.5402%/6.842/1/P = .0089 |
ADPR (acute demyelinating polyradiculopathy) | 2 | 0.40% | 0 | 0 | .4%/− 0.4793–1.5170%/1.842/1/P = 0.1748 |
ADEM: (acute disseminated encephalomyelitis) | 1 | 0.20% | 1 | 0.20% | 0%/− 1.0055–1.0055%/0.000/1/P = 1.0000 |
Inflammatory myositis | 3 | 0.60% | 0 | 0 | .6%/− 0.3215–1.8223%/2.765/1/P = 0.0963 |
Erythema nodosum | 1 | 0.20% | 0 | 0 | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Renal complication | 3 | 0.60% | 36 | 8% | 7.4%/4.9308%-10.2697%/30.573/1/P < 0.0001 |
Acute macular neuroretinopathy/facial palsy/choroiditis | 7 | 2% | 66 | 14% | 12%/8.6447–15.5942%/44.951/1/P < 0.0001 |
Cutaneous vasculitis | 0 | 0.00% | 1 | 0.20% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Myocarditis | 0 | 0.00% | 22 | 5% | 5%/3.1579–7.3908%/23.564/1/P < 0.0001 |
Acute myocardial infarction | 0 | 0.00% | 2 | 0.40% | .4%/− 0.4793–1.5170%/1.842/1/P = 0.1748 |
ITP | 0 | 0.00% | 4 | 0.80% | .8%/− 0.1674–2.1148%/3.691/1/P = 0.0547 |
Miller Fisher S | 0 | 0.00% | 1 | 0.20% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Sarcoid reaction | 0 | 0.00% | 1 | 0.20% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Steven Johnson Syndrome | 0 | 0.00% | 1 | 0.20% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Uveitis | 0 | 0.00% | 0 | 0.00% | 0%/− 0.8282–0.8282% |